Microsomal cytochrome P450-mediated metabolism of protopanaxatriol ginsenosides: Metabolite profile, reaction phenotyping, and structure-metabolism relationship

Drug Metabolism and Disposition

Volumn 38, Issue 10, 2010, Pages 1731-1739

  Hao, Haiping ^a   Lai, Li ^a,b   Zheng, Chaonan ^a   Wang, Qiong ^a   Yu, Guo ^a   Zhou, Xueyan ^a   Wu, Liang ^a   Gong, Ping ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A4; DRUG METABOLITE; GINSENOSIDE; GINSENOSIDE RE; GINSENOSIDE RF; GINSENOSIDE RG 1; GINSENOSIDE RH 2; GINSENOSIDE RH1; GLUCOSE; PROTOPANAXADIOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG ELIMINATION; DRUG METABOLISM; ENZYME KINETICS; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ION TRAP MASS SPECTROMETRY; MALE; MICROSOME; NONHUMAN; OXYGENATION; PHENOTYPE; PRIORITY JOURNAL; RAT; TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; ANIMALS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GINSENOSIDES; HUMANS; ISOENZYMES; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SAPOGENINS; STRUCTURE-ACTIVITY RELATIONSHIP; YOUNG ADULT;

RATTUS;

EID: 77957236253     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033845     Document Type: Article

References (47)

1. Attele AS, Wu JA, and Yuan CS (1999) Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58:1685-1693.
2. Bae EA, Han MJ, Kim EJ, and Kim DH (2004) Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res 27:61-67.
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
4. Bressler R (2005) Herb-drug interactions: interactions between ginseng and prescription medications. Geriatrics 60:16-17. (Pubitemid 41161304)
5. +/glucose cotransporter 1 expression. J Agric Food Chem 55:1993-1998.
6. Christensen LP (2009) Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 55:1-99.
7. Coon JT and Ernst E (2002) Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf 25:323-344. (Pubitemid 34634271)
8. Etheridge AS, Black SR, Patel PR, So J, and Mathews JM (2007) An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73:731-741. (Pubitemid 47234614)
9. Gillis CN (1997) Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol 54:1-8.
10. Gu Y, Wang GJ, Sun JG, Jia YW, Wang W, Xu MJ, Lv T, Zheng YT, and Sai Y (2009) Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. Food Chem Toxicol 47:2257-2268.
11. Hao H, Cui N, Wang G, Xiang B, Liang Y, Xu X, Zhang H, Yang J, Zheng C, Wu L, et al. (2008a) Global detection and identification of nontarget components from herbal preparations by liquid chromatography hybrid ion trap time-of-flight mass spectrometry and a strategy. Anal Chem 80:8187-8194.
12. Hao H, Wang G, Cui N, Li J, Xie L, and Ding Z (2007) Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab 8:137-149. (Pubitemid 46218680)
13. Hao M, Zhao Y, Chen P, Huang H, Liu H, Jiang H, Zhang R, and Wang H (2008b) Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One 3:e2697.
14. Jia L and Liu X (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8:822-829. (Pubitemid 350238912)
15. Jia L and Zhao Y (2009) Current evaluation of the millennium phytomedicine - ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Curr Med Chem 16:2475-2484.
16. Jia L, Zhao Y, and Liang XJ (2009) Current evaluation of the millennium phytomedicine - ginseng (II): collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem 16:2924-2942.
17. Kasai R, Hara K, Dokan R, Suzuki N, Mizutare T, Yoshihara S, and Yamasaki K (2000) Major metabolites of ginseng sapogenins formed by rat liver microsomes. Chem Pharm Bull (Tokyo) 48:1226-1227.
18. Lai L, Hao H, Liu Y, Zheng C, Wang Q, Wang G, and Chen X (2009a) Characterization of pharmacokinetic profiles and metabolic pathways of 20(S)-ginsenoside Rh1 in vivo and in vitro. Planta Med 75:797-802.
19. Lai L, Hao H, Wang Q, Zheng C, Zhou F, Liu Y, Wang Y, Yu G, Kang A, Peng Y, et al. (2009b) Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos 37:2399-2407.
20. Li GX and Liu ZQ (2008) The protective effects of ginsenosides on human erythrocytes against hemin-induced hemolysis. Food Chem Toxicol 46:886-892.
21. Liu H, Yang J, Du F, Gao X, Ma X, Huang Y, Xu F, Niu W, Wang F, Mao Y, et al. (2009) Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos 37:2290-2298.
22. Liu Y, Li W, Li P, Deng MC, Yang SL, and Yang L (2004) The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity. Biol Pharm Bull 27:1555-1560. (Pubitemid 41701638)
23. Liu Y, Ma H, Zhang JW, Deng MC, and Yang L (2006a) Influence of ginsenoside Rh1 and F1 on human cytochrome p450 enzymes. Planta Med 72:126-131.
24. Liu Y, Zhang JW, Li W, Ma H, Sun J, Deng MC, and Yang L (2006b) Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 91:356-364. (Pubitemid 43827288)
25. Liu YT, Hao HP, Liu CX, Wang GJ, and Xie HG (2007) Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 39:699-721.
26. Marechal JD, Yu J, Brown S, Kapelioukh I, Rankin EM, Wolf CR, Roberts GC, Paine MJ, and Sutcliffe MJ (2006) In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab Dispos 34:534-538.
27. Meyer MR, Peters FT, and Maurer HH (2009) Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochem Pharmacol 77:1725-1734.
28. Qian T, Cai Z, Wong RN, and Jiang ZH (2005a) Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Commun Mass Spectrom 19:3549-3554. (Pubitemid 41691930)
29. Qian T, Cai Z, Wong RN, Mak NK, and Jiang ZH (2005b) In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B Analyt Technol Biomed Life Sci 816:223-232. (Pubitemid 40143510)
30. Qian T, Jiang ZH, and Cai Z (2006) High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rat. Anal Biochem 352:87-96.
31. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
32. Sauer C, Peters FT, Schwaninger AE, Meyer MR, and Maurer HH (2009) Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. Biochem Pharmacol 77:444-450.
33. Sun HX, Chen Y, and Ye Y (2006) Ginsenoside Re and notoginsenoside R1: immunologic adjuvants with low haemolytic effect. Chem Biodivers 3:718-726. (Pubitemid 44193009)
34. Sun J, Hu S, and Song X (2007) Adjuvant effects of protopanaxadiol and protopanaxatriol saponins from ginseng roots on the immune responses to ovalbumin in mice. Vaccine 25:1114-1120. (Pubitemid 44937445)
35. Sun J, Wang G, Haitang X, Hao L, Guoyu P, and Tucker I (2005) Simultaneous rapid quantification of ginsenoside Rg1 and its secondary glycoside Rh1 and aglycone protopanaxatriol in rat plasma by liquid chromatography-mass spectrometry after solid-phase extraction. J Pharm Biomed Anal 38:126-132. (Pubitemid 40725098)
36. Tawab MA, Bahr U, Karas M, Wurglics M, and Schubert-Zsilavecz M (2003) Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 31:1065-1071. (Pubitemid 36975678)
37. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res 18:1071-1080. (Pubitemid 32900389)
38. Wang CZ and Yuan CS (2008) Potential role of ginseng in the treatment of colorectal cancer. Am J Chin Med 36:1019-1028.
39. Wang Y, Ye X, Ma Z, Liang Q, Lu B, Tan H, Xiao C, Zhang B, and Gao Y (2008) Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. Eur J Pharmacol 601:73-78.
40. Wang YZ, Chen J, Chu SF, Wang YS, Wang XY, Chen NH, and Zhang JT (2009) Improvement of memory in mice and increase of hippocampal excitability in rats by ginsenoside Rg1's metabolites ginsenoside Rh1 and protopanaxatriol. J Pharmacol Sci 109:504-510.
41. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686. (Pubitemid 39006760)
42. Xie HT, Wang GJ, Sun JG, Tucker I, Zhao XC, Xie YY, Li H, Jiang XL, Wang R, Xu MJ, et al. (2005) High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 818:167-173. (Pubitemid 40331821)
43. Xu M, Wang G, Xie H, Huang Q, Wang W, and Jia Y (2008) Pharmacokinetic comparisons of schizandrin after oral administration of schizandrin monomer, Fructus Schisandrae aqueous extract and Sheng-Mai-San to rats. J Ethnopharmacol 115:483-488. (Pubitemid 350299087)
44. Yang L, Deng Y, Xu S, and Zeng X (2007) In vivo pharmacokinetic and metabolism studies of ginsenoside Rd. J Chromatogr B Analyt Technol Biomed Life Sci 854:77-84. (Pubitemid 46962368)
45. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J Biol Chem 279:38091-38094.
46. Zheng C, Hao H, Wang X, Wu X, Wang G, Sang G, Liang Y, Xie L, Xia C, and Yao X (2009) Diagnostic fragment-ion-based extension strategy for rapid screening and identification of serial components of homologous families contained in traditional Chinese medicine prescription using high-resolution LC-ESI- IT-TOF/MS: Shengmai injection as an example. J Mass Spectrom 44:230-244.
47. Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, and Mitroka J (2005) Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 33:500-507. (Pubitemid 40393192)